What is 'Phase 2'

Phase 2 is the second phase of clinical trials or studies for an experimental new drug, in which the focus of the drug is on its effectiveness. The Center for Drug Evaluation and Research, or CDER, a division of the U.S. Food and Drug Administration, oversees these clinical trials.

Phase 2 trials typically involve hundreds of patients who have the disease or condition that the drug candidate seeks to treat. The main objective of Phase 2 trials is to obtain data on whether the drug actually works in treating a disease or indication, which is generally achieved through controlled trials that are closely monitored, while safety and side-effects also continue to be studied.

BREAKING DOWN 'Phase 2'

Phase 2 studies also aim to establish the most effective dosage for the drug, and the optimum delivery method. Phase 2 trials usually form the biggest stumbling block in the development of a new drug.

Phase 2 trials are typically constructed as double blind, randomized, placebo-controlled studies. This means that some of the patients enrolled in the study will receive the drug candidate, while others will receive a placebo or a different drug. The assignment is done on a random basis and neither the participant nor the clinical investigator knows whether the participant will be receiving the drug or the placebo. This randomness and anonymity is rigorously enforced to prevent bias in the studies.

Success rate and stock impact of phase 2 trials

Phase 2 trials are considered successful when analysis of the data from enrolled participants reveals that the experimental drug works in treating the disease or indication. Patients who have received the experimental drug should have better clinical outcomes on a statistically significant basis than those who received the placebo or the alternative drug. If Phase 2 trials are successful, the drug proceeds to Phase 3 studies.  

Phase 2 studies only commence if Phase 1 studies do not reveal unduly high toxicity or other safety risks of the experimental drug. While up to a third of drugs in Phase 1 studies do not progress to the Phase 2 stage because they are not safe enough, the odds of a drug progressing from Phase 2 to Phase 3 trials are even lower, about 32 percent to 39 percent.

Because of the relatively low rate of success at the Phase 2 stage, market reaction to a successful Phase 2 outcome is generally rewarded with significant stock price appreciation for the company developing the drug. The degree of stock appreciation depends on a number of factors including: the prevailing environment for equities in general and healthcare stocks in particular, the disease or indication that the drug aims to treat, the strength of the Phase 2 results, and price movement in the stock prior to the release of Phase 2 results.

RELATED TERMS
  1. Phase 1

    Phase 1 clinical studies or clinical trials are focused on evaluating ...
  2. Clinical Trials

    Clinical trials are studies of human volunteers for the purpose ...
  3. Phase 4

    Phase 4 refers to the final stage of new drug testing, which ...
  4. New Indications

    New indications is a term used by medical companies and professionals ...
  5. Consolidation Phase

    Consolidation phase is a stage in the industry life cycle where ...
  6. Orange Book

    The Orange Book is a list of drugs that the U.S. Food and Drug ...
Related Articles
  1. Investing

    5 Favorite Biotech Bets

    MoneyShow.com contributors have found potentially promising ideas within the small cap biotech space.
  2. Investing

    Corbus Gets FDA Green Light for Phase 3 Drug Study

    Corbus stock spiked after it announced that the FDA approved an upcoming Phase 3 drug study.
  3. Trading

    Market Cycles: The Key to Maximum Returns

    Understand the various phases of the market cycle, to avoid bubbles and make the best investments.
  4. Investing

    Foamix Acne Drug Fails Late-Stage Study

    Foamix Pharmaceuticals stock hit a 52-week low on failure of FMX101 drug a Phase 3 study.
  5. Investing

    3 of America's Most Expensive Drugs and Who Profits From Them

    Learn about orphan drugs that are some of the most expensive drugs in America. Read about the companies that manufacture these drugs.
  6. Investing

    Alnylam Expects Better 2017 After Setbacks

    After weathering setbacks, Alnylam is more positive about the future prospects for its drug programs.
  7. Investing

    Vertex Begins Two Cystic Fibrosis Studies (VRTX)

    Vertex Pharmaceuticals launched two Phase 2 studies to test a new class of cystic fibrosis drugs.
  8. Insights

    The Industry Handbook: Pharma Industry

    Learn about the pharmaceutical industry and discover the forces that influence this highly profitable and dynamic sector.
  9. Investing

    Drug Prices: Name Brands Doubled in Last 5 Years (ESRX)

    Express Scripts' Drug Trends Report, released Monday, revealed that the average price of brand name drugs rose 16.2% in 2015, with over one third of brand name drugs seeing price increases over ...
RELATED FAQS
  1. What are the three phases of a completed initial public offering (IPO) transformation ...

    An initial public offering (IPO) represents a private company's first offering of its equity to public investors. Read Answer >>
  2. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  3. What happens during the consolidation phase of an investor's life cycle?

    Unlike the accumulation phase – where emphasis is placed on growing wealth – the consolidation phase is a balance between ... Read Answer >>
  4. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
  5. What does it mean to have orphan drug status?

    The USDA incentivizes pharmaceutical companies to develop cures for rare diseases via the Office of Orphan Product Development. ... Read Answer >>
Hot Definitions
  1. Socially Responsible Investment - SRI

    Socially responsible investing looks for investments that are considered socially conscious because of the nature of the ...
  2. Business Cycle

    The business cycle describes the rise and fall in production output of goods and services in an economy. Business cycles ...
  3. Futures Contract

    An agreement to buy or sell the underlying commodity or asset at a specific price at a future date.
  4. Yield Curve

    A yield curve is a line that plots the interest rates, at a set point in time, of bonds having equal credit quality, but ...
  5. Portfolio

    A portfolio is a grouping of financial assets such as stocks, bonds and cash equivalents, also their mutual, exchange-traded ...
  6. Gross Profit

    Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of ...
Trading Center